Abstract Background and Aims Ever since their therapeutic introduction, SGLT2 inhibition class of medicaments did impress physicians of related fields, nephrologists, internal medicine doctors, endocrinologists etc. Their natriuretic and glucoretic effects besides lowering the plasma glucose does produce a important effect on lowering intraglomerular pressure, this became an added value and a strong point to recommend these drugs on all CKD population irregardles the main cause of the disease. Method Observational retrospective study on 125 patients, three groups: G1 50 pt with diabetic nephropathy treated with empagliflozine vs control group G2 50 pt with diabetic nephropathy treated with other glucose lowering agents, and G3 25 nondiabetic pt with CKD and proteinuria treated with SGLT2i. Inclusion criteria was proteinuria and T2D for G1 and G2, and patients with proteinuria and CKD for G3. Patients with T1D and eGFR > 20 where excluded. Intervention - the SGLT2i drugs where started, median follow up 18 months. We followed on four periods creatinine levels, 24 hour proteinuria in g/24 h, HbA1c, cholesterol level, BMI. Results In our study the G1 showed a decrease in proteinuria average – 811 mg/24 h, serum creatinine showed increase on the first three months and it did get back to baseline afterwards, the eGFR increased + 15.44 ml/min; HbA1c decreased with -1.41%, levels, the reduction BMI – 0.9 kg/m2 and LDL cholesterol -1.11 mmol/l. G2 results decrease on 24 hour proteinuria with – 121 mg/24 hours, a drop on eGFR with - 3.3 ml/min, a drop on HbA1C – 1.45 %, - 0.3 mmol/l decrease on cholesterol level and average increase on BMI with + 0.8 kg/m2; G3 results on patients without T2D but with CKD different causes and proteinuria where: - 690 decrease proteinuria, + 14.4 increase on eGFR, HbA1C NA, we did have 2 cases that experienced hypoglycemic symptoms, both of them where improved with dose reduction, a – 0.9 decrease on cholesterol level and 0.3 kg/m2 was registered on our G3. Conclusion In our observation the 18 month follow up showed remarkable improve in kidney function tests, other benefits were noted such as optimal glycemic control, total body cholesterol lowering and a significant reduce of body weight expressed on BMI. Treatment with SGLT2i drugs does present a safe and efficient treatment modality for diabetic nephropathy and for all other CKD with proteinuria.